NEW YORK (GenomeWeb News) – Alacris Theranostics today said that is has gained Illumina CSPro certification for next-generation sequencing.
Illumina CSPro is a collaborative service provider partnership aimed at providing high quality data for genetic analysis applications, and applicants undergo a two-phase process that includes minimum data generation, data certification, and an onsite audit of the facility and processes.
Based in Berlin, Alacris specializes in personalized medicine for cancer patient diagnosis, treatment, and stratification, it said on its website. It uses a systems biology approach, called ModCell, developed at the Max Planck Institute for Molecular Genetics and licensed to Alacris. The approach is based on next-generation sequencing to provide information about the genome and transcriptome, and incorporates kinetic pathway information, and mutation and drug databases.